9 completed, 1 unknown. 10 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 9, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Chikungunya Fever: new trials by email Literature Review of Chikungunya Fever trials Research Report on Chikungunya Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of an Inactivated Chikungunya Virus Vaccine HydroVax-005 CHIKV, Placebo - Chikungunya Fever, Chikungunya Virus | Phase 1 | Completed | Najit Technologies, Inc. | 48 | 2024-11-04 | 2026-03-19 |
| Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico. CHIK low dose, CHIK mid dose, CHIK high dose - Chikungunya, Zika | Phase 1 | Completed | University of Oxford | 120 | 2020-10-23 | 2022-03-23 |
| Phase 1 Study of SAR440894 vs Placebo Placebo, SAR440894 - Chikungunya Virus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2020-10-14 | 2026-01-13 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults mRNA-1944, Placebo - Prevention of Chikungunya Virus Infection | Phase 1 | Completed | ModernaTX, Inc. | 39 | 2019-01-22 | 2021-07-07 |
| Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001) ChAdOx1 Chik - Chikungunya Fever | Phase 1 | Completed | University of Oxford | 24 | 2018-07-31 | 2019-10-18 |
| Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers VLA1553 - Chikungunya | Phase 1 | Completed | Valneva Austria GmbH | 120 | 2018-03-05 | 2019-08-29 |
| Phase I Trial of Measles Vectored Chikungungya Vaccine Placebo, VRC-CHKVLP059-00-VP - Chikungunya Virus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 2017-05-30 | 2020-11-27 |
| Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine Inactivated Chikungunya virus vaccine 20 mcg, Inactivated Chikungunya virus vaccine 30 mcg, Inactivated Chikungunya virus vaccine 10 mcg - Chikungunya | Phase 1 | Completed | Bharat Biotech International Limited | 60 | 2017-04-17 | 2020-10-28 |
| Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins anti-CHIKV hyperimmune immunoglobulins - Chikungunya Virus Infection | Phase 1 / Phase 2 | Unknown | Centre Hospitalier Universitaire de la Guadeloupe | 40 | 2014-09-01 | 2014-11-03 |
| Chikungunya Virus Vaccine Trial in Healthy Adults VRC-CHKVLP059-00-VP - Viral Vaccines, Chikungunya Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2011-12-01 | 2016-07-25 |
Alphavirus Infections (1) · Measles (1) · Virus Diseases (1) · Zika Virus Infection (1)
Arbovirus Infections (10) · Infections (10) · Mosquito-Borne Diseases (10) · RNA Virus Infections (10) · Togaviridae Infections (10) · Vector Borne Diseases (10) · Alphavirus Infections (9) · Virus Diseases (9) · Flaviviridae Infections (1) · Flavivirus Infections (1) · Mononegavirales Infections (1) · Morbillivirus Infections (1) · Paramyxoviridae Infections (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · University of Oxford (2) · Bharat Biotech International Limited (1) · Centre Hospitalier Universitaire de la Guadeloupe (1) · ModernaTX, Inc. (1) · Najit Technologies, Inc. (1) · Valneva Austria GmbH (1)
United States (6) · France (1) · India (1) · Mexico (1) · United Kingdom (1)
Adrian V Hill, DPhill FRCP (1) · Julie E Ledgerwood, D.O. (1) · Krishna Mohan, PHD (1) · Nina Wressnigg (1)
PMID 25132507, PMID 32497524, PMID 34330906, PMID 34887572, PMID 35210606
2014 (1), U44AI152995 (1)